These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 15155136)

  • 21. Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: Will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions?
    Reikvam H; Kittang AO; Melve G; Mosevoll KA; Bentsen PT; Ersvær E; Gjertsen BT; Bruserud Ø
    Curr Cancer Drug Targets; 2013 Jan; 13(1):30-47. PubMed ID: 22873213
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histone modification enzymes: novel targets for cancer drugs.
    Kristeleit R; Stimson L; Workman P; Aherne W
    Expert Opin Emerg Drugs; 2004 May; 9(1):135-54. PubMed ID: 15155140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: a prospective randomized Dutch-Belgian Haemato-Oncology Co-operative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial.
    Breems DA; Boogaerts MA; Dekker AW; Van Putten WL; Sonneveld P; Huijgens PC; Van der Lelie J; Vellenga E; Gratwohl A; Verhoef GE; Verdonck LF; Löwenberg B
    Br J Haematol; 2005 Jan; 128(1):59-65. PubMed ID: 15606550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia.
    Ferrara F; Palmieri S; Mele G
    Haematologica; 2004 Aug; 89(8):998-1008. PubMed ID: 15339685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute myeloid leukemia: therapeutic impact of epigenetic drugs.
    Altucci L; Clarke N; Nebbioso A; Scognamiglio A; Gronemeyer H
    Int J Biochem Cell Biol; 2005 Sep; 37(9):1752-62. PubMed ID: 15964234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Farnesyltransferase inhibitors (FTIs) in myeloid malignancies.
    Karp JE; Lancet JE
    Ann Hematol; 2004; 83 Suppl 1():S87-8. PubMed ID: 15124688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk acute myeloid leukemia: results of the EMA 2000 trial.
    Thomas X; Elhamri M; Chelghoum Y; Reman O; Arnaud P; Raffoux E; Le QH; Tavernier E; Dombret H; Michallet M
    Ann Hematol; 2005 Jun; 84(6):376-82. PubMed ID: 15782343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Curing childhood acute myeloid leukemia (AML) at the half-way point: promises to keep and miles to go before we sleep.
    Woods WG
    Pediatr Blood Cancer; 2006 May; 46(5):565-9. PubMed ID: 16261562
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute myelogenous leukemia.
    Shipley JL; Butera JN
    Exp Hematol; 2009 Jun; 37(6):649-58. PubMed ID: 19463767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of childhood acute myeloid leukemia.
    ter Bals E; Kaspers GJ
    Expert Rev Anticancer Ther; 2005 Oct; 5(5):917-29. PubMed ID: 16221060
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging treatment strategies for acute myeloid leukemia (AML) in the elderly.
    Kuendgen A; Germing U
    Cancer Treat Rev; 2009 Apr; 35(2):97-120. PubMed ID: 18951721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incorporating novel treatment strategies into conventional therapy.
    Estey EH
    Clin Adv Hematol Oncol; 2009 Jun; 7(6):4-7. PubMed ID: 19645129
    [No Abstract]   [Full Text] [Related]  

  • 34. Limited value of FLT3 mRNA expression in the bone marrow for prognosis and monitoring of patients with acute myeloid leukemia.
    Kainz B; Fonatsch C; Schwarzinger I; Sperr WR; Jäger U; Gaiger A
    Haematologica; 2005 May; 90(5):695-6. PubMed ID: 15921390
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecularly targeted therapies in myelodysplastic syndromes and acute myeloid leukemias.
    Morgan MA; Reuter CW
    Ann Hematol; 2006 Mar; 85(3):139-63. PubMed ID: 16391911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intensified induction therapy for children with AML.
    Woods WG
    Ann Hematol; 2004; 83 Suppl 1():S119-20. PubMed ID: 15124701
    [No Abstract]   [Full Text] [Related]  

  • 37. Novel therapeutic agents in acute myeloid leukemia.
    Stone RM
    Exp Hematol; 2007 Apr; 35(4 Suppl 1):163-6. PubMed ID: 17379102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
    Kuchenbauer F; Kern W; Schoch C; Kohlmann A; Hiddemann W; Haferlach T; Schnittger S
    Haematologica; 2005 Dec; 90(12):1617-25. PubMed ID: 16330434
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical trials in adult AML.
    Stock W
    Clin Adv Hematol Oncol; 2009 Jun; 7(6):8-10. PubMed ID: 19645130
    [No Abstract]   [Full Text] [Related]  

  • 40. Ajoene (natural garlic compound): a new anti-leukaemia agent for AML therapy.
    Hassan HT
    Leuk Res; 2004 Jul; 28(7):667-71. PubMed ID: 15158086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.